Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CASI Acquires China Rights to Lymphoma Chemotherapy from Mundipharma

publication date: Aug 2, 2023

CASI Pharma, a Maryland-Beijing biopharma, acquired China distribution rights to Folotyn® (pralatrexate) from Mundipharma International. Folotyn® is a dihydrofolate reductase inhibitor that is approved in China and the US for relapsed or refractory peripheral T-cell lymphoma (PTCL). The chemotherapy is made by global marketing company, Acrotech Biopharma. Folotyn is a natural fit for CASI, a company that focuses on acquiring and developing therapies for hematological cancers along with other areas of unmet medical need. Terms of the agreement were not disclosed. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital